Sullivan Lynne Marie — SEC Form 4 filings
SEC reporting owner CIK 1727640. 12 Form 4 filings on record with FilingPulse; latest filed 2026-06-11.
Transaction summary — filings shown
Covers all 12 filings on record, filed 2024-06-13 to 2026-06-11. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 5 legs across 5 filings — 22,619 shares, $23,706 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 8.
- Largest priced transaction: sale of 21,867 shares @ $1.03 ($22,523) in Unity Biotechnology, Inc., filed 2025-04-03.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Unity Biotechnology, Inc. (UBX) | CFO & Head of Corp. Dev. | 7 | — | 5 legs · 22,619 sh · $23,706 | 3 |
| Solid Biosciences Inc. (SLDB) | Director | 3 | — | — | 3 |
| Inozyme Pharma, Inc. (INZY) | Director | 2 | — | — | 2 |
Form 4 filings — Sullivan Lynne Marie
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-11 | 4 | Solid Biosciences Inc. (SLDB) | Grant/award (A): 77,500 (derivative) @ $0 | EDGAR |
| 2025-07-03 | 4 | Inozyme Pharma, Inc. (INZY) | Disposition to issuer (D): 28,368 (derivative) | EDGAR |
| 2025-06-13 | 4 | Solid Biosciences Inc. (SLDB) | Grant/award (A): 77,500 (derivative) @ $0 | EDGAR |
| 2025-04-03 | 4 | Unity Biotechnology, Inc. (UBX) | Sale (S): 21,867 @ $1.03 | EDGAR |
| 2025-03-31 | 4 | Unity Biotechnology, Inc. (UBX) | Grant/award (A): 65,000 @ $0 · Grant/award (A): 106,000 (derivative) @ $0 | EDGAR |
| 2025-02-05 | 4 | Unity Biotechnology, Inc. (UBX) | Sale (S): 153 @ $2.23 | EDGAR |
| 2025-01-23 | 4 | Unity Biotechnology, Inc. (UBX) | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2024-11-06 | 4 | Unity Biotechnology, Inc. (UBX) | Sale (S): 136 @ $1.29 | EDGAR |
| 2024-08-06 | 4 | Unity Biotechnology, Inc. (UBX) | Sale (S): 139 @ $1.53 | EDGAR |
| 2024-06-26 | 4 | Unity Biotechnology, Inc. (UBX) | Sale (S): 324 @ $1.40 | EDGAR |
| 2024-06-20 | 4 | Inozyme Pharma, Inc. (INZY) | Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | Solid Biosciences Inc. (SLDB) | Grant/award (A): 34,400 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1727640 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →